[The leuko-stimulating and protective action of human recombinant interleukin-1 beta (betaleukin) in the chemotherapy of malignant tumors].

The investigation was concerned with the leuko-stimulating effect of interleukin-1 beta injected subcutaneously (4.6 +/- 0.3 ng/kg body), daily, for 10 days, to treat toxic leukopenia and neutropenia stage III in cancer patients.

[Betaleukin (human recombinant interleukin-1beta) for the prevention and correction of toxic leukopenia in chemotherapy of malignant neoplasms].

The marked and quick response to betaleukin, a preparation of recombinant human interleukin-1 beta, was demonstrated in 77 cases of extensive solid neoplasms and non-Hodgkin's disease, suffering combination chemotherapy-induced toxic leukopenia. Leukopoiesis was effectively stimulated by intravenous administration, of 10-20 ng/kg weight, dropwise for 5 days. Due to adjuvant betaleukin in identical dosage, chemotherapy was continued, in moderate leukopenia, without causing leukocyte count to drop.

[An interleukin-1 beta efficacy study in the treatment of combined radiation-thermal lesions].

The experiments were carried out on F1 (CBA x C57B16) male-mice. It was shown that, in contrast to a therapeutic effect of IL-1 for the solely irradiated mice, a single subcutaneous injection of 100 micrograms/kg recombinant human IL-1 beta in 4 h after a combined radiation-thermal injury (CRTI) increased significantly the death rate of the animals within the first 2-4 days. Administration of 150 ng IL-1 per mouse in 4, 24, or 48 h after the CRTI decreased an average life-span of mice.

[Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors].

Clinical studies were carried out in a group of 71 cancer patients to evaluate the effects of intravenous infusion of human recombinant interleukin-1-beta (betaleukin) (I and II phases). It was shown that daily single doses of 10-20 ng/kg body, for 5 days, markedly stimulated leukopoiesis (granulocytopoiesis) in toxic (grade II-IV) leukopenia which hampered combination chemotherapy. A protective effect on leukopoiesis (granulocy-topoiesis) was recorded in cases of moderate leukopenia when chemotherapy was continued.

[Structural and functional analysis of the human immunodeficiency glycoprotein gp120 with homologous synthetic peptides].

The purpose of the study was to identify sites of gp 120, which are responsible for CD4 binding and induce tumor necrosis factor-alpha (TNF-alpha) synthesis. Seven peptides were synthesized from gp 120. The peptides were studied in the following biological tests: binding to CD4 molecules of the Jurkat cell clones 3G6 and PBMC of healthy persons.

[A granulopoiesis inhibitor. Synthesis and biological activity].

Three schemes of synthesis for pentapeptide Glp-Glu-Asp-Cys-Lys-OH were compared was carried out. Acetamidomethyl protection was used for the mercapto group of cysteine. For the same purpose, cystine was used as the starting compound for synthesis.

[Coxiella burnetii antigens--inducers of tumor necrosis factor and interleukin-1].

The cultivation of mouse peritoneal macrophages in the presence of antigenic preparations obtained from C.burnetii was accompanied by the appearance of phagocytes and considerable amounts of tumor necrosis factor and interleukin 1 in the culture medium. The production of cytokines depended on the doses of preparations used as inducers.

[Lipid peroxidation in experimental glaucoma and the possibilities for its correction (preliminary report)].

Lipid peroxidation products and intraocular pressure were measured in 10 rabbits with adrenalin-induced glaucoma, and the possibility of correcting these parameters with a bioantioxidant was tested. Intraocular pressure and levels of lipid peroxidation products in rabbit blood sera were found to grow in the course of adrenalin injections. Intraocular pressure significantly reduced and lipid peroxidation normalized after subconjunctival administration of a bioantioxidant.

[Interconnection of interleukin-1 and glucocorticoid hormones in regulating the immune response].

IL-1 and hydrocortisone have an opposite and competitive effect on the lymphocyte proliferation in cell culture. In mice recombinant human IL-1 beta dose-dependently induces high level serum corticosterone. Injection of IL-1 beta or hydrocortisone led to a similar alterations in the thymus: reduction of cellularity and decrease in spontaneous thymocyte proliferation.

[The content of interleukin-1 beta in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis].

The enzyme immunoassay determined serum levels of interleukin-1 beta (IL-1 beta) in 35 patients with systemic lupus erythematosus (SLE) and 18 rheumatoid arthritis (RA) patients. In high activity of both SLE and RA as well as in the presence of fever, anemia, marked skin vasculitis IL-1 beta rose high, still higher levels being reported in patients with erosive joints compared to those in RA patients with initial stage of RA. Lower IL-1 beta content often marked nephropathy in both the diseases.

[The level of the tumor necrosis factor in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis].

The contents of tumor necrosis factor alpha (TNF alpha) was measured by enzyme immunoassay in the serum from 43 healthy donors against 49 patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). In all the donors the cytokine did not reach 50 pg/ml, in SLE and RA running actively TNF alpha levels got elevated in the absence of previous long-term immunocorrection. Under the treatment effect blood levels of the cytokine fell in inhibition of the autoimmune process.

[The effect of recombinant interleukin-1 beta on the chemotactic activity of neutrophilic leukocytes].

The role of interleukin-1 in the activation of neutrophils, the main effects of inflammatory reaction, is still unclear. This study has demonstrated that the recombinant preparation interleukin-1 beta (IL-1 beta) which the authors have obtained fails to produce a direct action on the locomotor functions of neutrophils. At the same time, injection of IL-1 beta in mice leads to neutrophilic migration to the injection site and their efflux into peripheral blood.

[The biological activity of human recombinant interleukin-1 beta when administered in vivo].

Human recombinant IL-1 beta injected intraperitoneally into CBA mice dose-dependently induced leukocytosis, stimulated phagocytosis and reduced tetrazolium nitroblue by peritoneal leukocytes, colony formation by bone marrow cells, enhanced Con A and IL-2-induced proliferation and IL-2 production in thymocytes and splenocytes. Recombinant IL-1 beta restored bone marrow cell proliferation reduced after 5-fluorouracil treatment and significantly increased the survival rates of lethally irradiated mice.

[Tumor necrosis factor-alpha and interleukin-1beta in the blood plasma of patients with HIV infection].

The paper presents examination findings of 67 HIV-infected patients: 32 children aged 2.5 to 16 years and 35 adults aged 21 to 46 years. The proportion of patients with higher alpha-tumor necrosis factor and interleukin-1 beta increased with progression of the disease, the two parameters being higher in the children than in the adults.

[Immunocytochemical analysis of interleukin-1 beta production by human monocytes].

IL-1 was localized within the cytoplasm of human blood monocytes by indirect immunofluorescence using polyclonal rabbit antibodies. After LPS stimulation first IL-1-positive cells appeared at 2 hours and maximal intracellular IL-1 concentration was observed at 10-24 hours when nearly 90% monocytes were labeled with subsequent decline at 48 hours. The highest intracellular IL-1 content preceded its maximal level in cell supernatants.

[Molecular cloning of cDNA encoding human prointerleukin-6].

The data are presented on the cloning and sequencing of cDNA coding for human interleukin-6. The variability of cDNA proIL-6 cloned from different cellular sources was studied. The variability of cDNA proIL-6 may be expressed as heterogeneity of 5'- and 3'-end sequences of cDNA as well as single base-pair changes.

[Dynamics of production of interleukin-1 by monocytes after hemosorption in patients with peptic ulcer].

The spontaneous and induced production of monokine++-interleukin-1 (IL-1) by the peripheral blood monocytes under the influence of autotransfusions of hemosorbent-treated blood (AHTB) was studied in 22 patients with an unfavorable course of ulcer disease. The spontaneous production of IL-1 was found to grow successively after a course of AHTB in patients with ulcer disease with terms of cicatrization more than 2 weeks. In patients with slow cicatrization of ulcers the IL-1 production did not change.

[Production of interleukin-1 by peripheral blood monocytes in children with respiratory diseases].

Overall 111 healthy children aged 3 to 7 years, 71 children with ARVI and those aged 2 to 14 years with ARVI complicated by bronchitis and pneumonia were examined. The level and rate of IL-1 production by peripheral blood monocytes in response to lipopolysaccharide (LPS) were determined. It has been established that 98.

[The effect of recombinant human interleukin-1 beta on the repopulation of bone-marrow colony-forming cells in mice subjected to the action of radiation and burns].

The radioprotective and restorative (therapeutic) effects of human recombinant interleukin-1 beta (IL-1 beta) on the population of bone marrow CFU-S of mice, subjected to either sublethal doses of ionising irradiation itself or the same irradiation in combination with thermal burn, are investigated. Both the effects of the agent are registered under both in vitro and in vivo irradiation in semi-, syn- and allogeneic animals. If the irradiation was combined with thermal burn, the "therapeutic" effect of the agent was demonstrated at irradiation dose equal to 3.